Masters in Business

Josh Wolfe Discusses Innovative Investments (Podcast)

Aug 16, 2019
Josh Wolfe, co-founder of Lux Capital and a venture capital innovator, delves into the intersection of science and investment. He shares his journey from molecular biology to venture capital, offering insights into the importance of skepticism in evaluating startups, particularly in light of the Theranos case. Wolfe discusses the evolution of 3D printing, exploring its ethical implications and revolutionary applications. The conversation also highlights the transformative potential of technologies like CRISPR and the impact of GPUs in AI and defense, all while emphasizing the importance of diverse perspectives in investment.
Ask episode
AI Snips
Chapters
Books
Transcript
Episode notes
INSIGHT

Theranos: Delusion and Fraud

  • Theranos's failure stemmed from both delusion and fraud, highlighting the challenge of distinguishing between the two in early-stage ventures.
  • The lack of medical expertise on the board contributed to Theranos's downfall.
INSIGHT

Balancing Optimism and Pessimism

  • Lux Capital thrives on the contrasting dispositions of its co-founders, Josh Wolfe and Peter Hebert.
  • Wolfe's pessimism balances Hebert's optimism, creating a balanced approach to investment.
ADVICE

Avoiding Competition

  • Seek high scientific and technical complexity to avoid competition.
  • Funding easier ventures leads to numerous competitors, making it harder to pick winners.
Get the Snipd Podcast app to discover more snips from this episode
Get the app